Chemical formula: C₂₇H₃₈N₂O₄ Molecular mass: 454.602 g/mol PubChem compound: 2520
Verapamil is indicated for:
Population group: only adults (18 years old or older)
The management of mild to moderate hypertension and renal hypertension, used alone or in combination with other antihypertensive therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For the management and prophylaxis of angina pectoris.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old)
The treatment and prophylaxis of paroxysmal supraventricular tachycardia and the reduction of the ventricular rate in atrial fibrillation/flutter. Verapamil should not be used for atrial fibrillation/flutter in patients with Wolff-Parkinson-White syndrome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)
The treatment and prophylaxis of paroxysmal supraventricular tachycardia and the reduction of the ventricular rate in atrial fibrillation/flutter. Verapamil should not be used for atrial fibrillation/flutter in patients with Wolff-Parkinson-White syndrome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
For the management and prophylaxis of angina pectoris.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
The treatment and prophylaxis of paroxysmal supraventricular tachycardia and the reduction of the ventricular rate in atrial fibrillation/flutter. Verapamil should not be used for atrial fibrillation/flutter in patients with Wolff-Parkinson-White syndrome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old)
The treatment and prophylaxis of paroxysmal supraventricular tachycardia and the reduction of the ventricular rate in atrial fibrillation/flutter. Verapamil should not be used for atrial fibrillation/flutter in patients with Wolff-Parkinson-White syndrome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)
The treatment and prophylaxis of paroxysmal supraventricular tachycardia and the reduction of the ventricular rate in atrial fibrillation/flutter. Verapamil should not be used for atrial fibrillation/flutter in patients with Wolff-Parkinson-White syndrome.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Verapamil is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
